Meeting
2019 ASCO Annual Meeting
Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.
Authors
Anthony B. El-Khoueiry
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Anthony B. El-Khoueiry , Jacob Stephen Thomas , Diana L. Hanna , Lillian L. Siu , Nilofer Saba Azad , Giles Francis Whalen , Lewis H. Bender , Ian B. Walters , Anthony J. Olszanski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT 03058289
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2602)
DOI
10.1200/JCO.2019.37.15_suppl.2602
Abstract #
2602
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].](https://d201v5jt9ylckg.cloudfront.net/288/14408/208006/208006_A1471_poster_pv.jpg)
INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].
First Author: Matthew Ingham
Poster
2020 ASCO Virtual Scientific Program
Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
First Author: Jacob Stephen Thomas
Poster
2023 ASCO Annual Meeting
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
First Author: Christian Frederick Meyer
Poster
2022 ASCO Annual Meeting
![Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].](https://d201v5jt9ylckg.cloudfront.net/288/14354/207587/207587_A1412_poster_pv.jpg)
Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
First Author: Jacob Stephen Thomas